Clinical Trial Update: A Study of VX-659 Combination Therapy in CF Subjects Homozygous for F508del (F/F) [Phase 3]

View source ↗

Summary

Phase 3 study update for VX-659 combination therapy in cystic fibrosis patients homozygous for F508del (F/F) has completed with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• VX-659 (VX-659)

Snippet

Sponsor: Vertex Pharmaceuticals Incorporated | Conditions: Cystic Fibrosis | Phase 3 | Status: COMPLETED | Results posted: 2019-10-17